Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.45 |
| ▸ | FLT1 | P17948 | 1/20 | 0.45 |
| ▸ | FLT4 | P35916 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9796338 | 0.83 | NPSR1 (0.49) | NPSR1KDM4EALDH1A1PTPN11POLB | |
| SCHEMBL3756242 | 0.82 | ALDH1A1 (0.55) | NPSR1KDM4EALDH1A1PTPN11FLT1 | |
| SCHEMBL9796022 | 0.82 | ADAMTS4 (0.49) | NPSR1KDM4EALDH1A1PTPN11POLB | |
| SCHEMBL3764291 | 0.82 | NPSR1 (0.50) | NPSR1KDM4EALDH1A1PTPN11POLB | |
| SCHEMBL29894018 | 0.80 | APEX1 (0.54) | KDM4EALDH1A1FLT1FLT4KDR | |
| SCHEMBL3764440 | 0.79 | NPSR1 (0.46) | NPSR1KDM4EALDH1A1PTPN11FLT1 | |
| SCHEMBL7433558 | 0.79 | S1PR3 (0.53) | NPSR1KDM4EALDH1A1GAA | |
| SCHEMBL3324916 | 0.79 | LMNA (0.42) | ALDH1A1L3MBTL1 | |
| SCHEMBL13543499 | 0.79 | CYP3A4 (0.52) | NPSR1KDM4EALDH1A1PTPN11GAA | |
| SCHEMBL3923738 | 0.79 | LMNA (0.62) | NPSR1KDM4EALDH1A1POLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100305093-A1 | Inhibitors of mTOR and Methods of Making and Using | EXELIXIS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| WO-2010118208-A1 | BENZOXAZEPIN-4- (5H) -YL DERIVATIVES AND THEIR USE TO TREAT CANCER | EXELIXIS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305093-A1 | Inhibitors of mTOR and Methods of Making and Using | MTOR, RICTOR, RPTOR | NPSR1 2952/4885KDM4E 718/4885ALDH1A1 3391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.